Winning Stock Forecast: Arrowhead Pharmaceuticals (NASDAQ: ARWR) Returns up to 321.18% in 1 Year


Since the beginning of 2018 Arrowhead Pharmaceuticals showed growth catalysts for this year. First, according to the quarterly report for the period ended December 31, 2017, on September 28, 2016 the Company entered into a collaboration agreement with Amgen Inc. The Company received a worldwide license for ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target, that makes Amgen wholly responsible for clinical development and commercialization of this technology. Moreover, the Company has sold 3,002,793 common stocks to Amgen at a price of $7.16 each. This agreement seems to be still fruitful.

The Company entered into the license agreement with Janssen Pharmaceuticals, Inc. (part of the Janssen Pharmaceuticals Companies of Johnson & Johnson) for ARO-HBV and collaboration for up to three RNAi therapeutic candidates that use TRiM TM platform. The total deal value is approximately $3.7 billion. Additionally, on January 18, 2018 Arrowhead announced the pricing of an underwritten public offering of 10 million  shares of its common stock at a price of $5.25 per share, before underwriting discounts. Net proceeds to the Company were approximately $56.7 million after deducting underwriting commissions and discounts and other offering expenses payable by the Company. This IPO gave undoubtedly a strong boost to the company’s finances. At the end of 2017, Arrowhead declared $11.5 million in cash, and $39.2 million in short-term investments.


I Know First’s Outlook

Best Stocks Under 5

ARWR stock is one of the most predictable assets by I Know First’s AI algorithm and the above annual prediction provided an impressive result – the return totaled to 321.18%. Arrowhead stock was already mentioned in our previous winning stock forecast for different investment horizons, for instance our 3 months Winning stock forecast based on this bullish prediction by I Know First AI algorithm. In accordance with the our 1 year prediction for ARWR the stock price followed the below path:

Algorithmic traders utilize daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster.

To learn how you can become a subscriber today, click here.

Please note-for trading decisions use the most recent forecast.

The Company

Arrowhead Pharmaceuticals (NASDAQ: ARWR) develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company’s preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company’s pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-HBV is designed to silence the production of all hepatitis B virus (HBV) gene products. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency (AATD). ARO-AAT is designed to knock down the Alpha-1 antitrypsin (AAT) gene transcript and reduce the hepatic production of the mutant AAT protein.